A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis.
NCT01902511 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2016-11-22
Summary
This will be a randomized double blind study which will be conducted on patients admitted to Department of Hepatology from June 2013 to may 2014 at ILBS, New Delhi. Patients not having any exclusion criteria will undergo bone marrow examination and liver biopsy at the baseline.
60 patients of decompensated cirrhosis will be randomised into two limbs- limb A (30 patients) will receive G-CSF and erythropoietin while those on limb B (30 patients) will receive G-CSF alone. The drugs will be given for 2 months and patient will be followed for 1 year. G-CSF will be given at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 60 (total 22 doses). Erythropoietin will be given s/c at dose of 500 IU/Kg twice a week for 2 months.
Follow up will be done on days 0,3,7,14,28, day 42 (6 weeks), day 60 (2 months), day 90 (3 months), day 180 (6 months), day 270 (9 months); and day 360 (1 year).
Conditions
- Decompensated Cirrhosis
Interventions
- DRUG
-
G-CSF+Erythropoetin
- DRUG
-
G-CSF
Sponsors & Collaborators
-
Institute of Liver and Biliary Sciences, India
lead OTHER
Principal Investigators
-
Dr Lovkesh Anand, MD · Institute of Liver & Biliary Sciences.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-07-31
- Primary Completion
- 2015-12-31
- Completion
- 2015-12-31
Countries
- India
Study Locations
More Related Trials
-
Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis
NCT01820208 ·Status: COMPLETED ·Phase: NA
-
Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
NCT02868164 ·Status: WITHDRAWN ·Phase: NA
-
Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.
NCT04066179 ·Status: UNKNOWN ·Phase: NA
-
To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).
NCT03162419 ·Status: WITHDRAWN ·Phase: NA
-
A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis
NCT01877759 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT
NCT03911037 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis
NCT03529136 ·Status: UNKNOWN ·Phase: PHASE2
-
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
NCT02721264 ·Status: UNKNOWN ·Phase: NA
-
Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells
NCT00913289 ·Status: TERMINATED ·Phase: PHASE1
-
Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis
NCT02297867 ·Status: COMPLETED ·Phase: PHASE1
-
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial
NCT07131306 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance
NCT02234440 ·Status: COMPLETED ·Phase: NA
-
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1b)
NCT05984303 ·Status: UNKNOWN ·Phase: PHASE1
-
Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis
NCT04243681 ·Status: COMPLETED ·Phase: PHASE4
-
Intrahepatic Reinfusion of CD133+ Stem Cells in Cirrhotic Patients
NCT01025622 ·Status: UNKNOWN ·Phase: PHASE1
-
Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure
NCT02857010 ·Status: TERMINATED ·Phase: PHASE1
-
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
NCT01483248 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
NCT02331745 ·Status: UNKNOWN ·Phase: PHASE4
-
Recombinant Human Granulocyte Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis
NCT03123666 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis
NCT01440309 ·Status: UNKNOWN ·Phase: PHASE1
-
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
NCT05121870 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure
NCT01383460 ·Status: COMPLETED ·Phase: PHASE3
-
Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells
NCT01062750 ·Status: COMPLETED ·Phase: NA
-
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Phase I Study on Safety and Efficacy of Mesenchymal Stem-Cell (MSC) Therapy in Non-Viral Acute-on-Chronic Liver Failure (ACLF)
NCT07131540 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients
NCT06740149 ·Status: RECRUITING ·Phase: PHASE1/PHASE2